Abstract
The potential of total choline (tCho), apparent diffusion coefficient (ADC) and tumor volume, both individually and in combination of all these three parameters (multi-parametric approach), was evaluated in predicting both pathological and clinical responses in 42 patients with locally advanced breast cancer (LABC) enrolled for neoadjuvant chemotherapy (NACT). Patients were sequentially examined by conventional MRI; diffusion weighted imaging and in vivo proton MR spectroscopy at 4 time points (pre-therapy, after I, II, and III NACT) at 1.5 T. Miller Payne grading system was used for pathological assessment of response. Of the 42 patients, 24 were pathological responders (pR) while 18 were pathological non-responders (pNR). Clinical response determination classified 26 patients as responders (cR) while 16 as non-responders (cNR). tCho and ADC showed significant changes after I NACT, however, MR measured tumor volume showed reduction only after II NACT both in pR and cR. After III NACT, the sensitivity to detect responders was highest for MR volume (83.3% for pR and 96.2% for cR) while the specificity was highest for ADC (76.5% for pR and 100% for cR). Combination of all three parameters exhibited lower sensitivity (66.7%) than MR volume for pR prediction, however, a moderate improvement was seen in specificity (58.8%). For the prediction of clinical response, multi-parametric approach showed 84.6% sensitivity with 100% specificity compared to MR volume (sensitivity 96.2%; specificity 80%). Kappa statistics demonstrated substantial agreement of clinical response with MR volume (k = 0.78) and with multi-parametric approach (k = 0.80) while moderate agreement was seen for tCho (k = 0.48) and ADC (k = 0.46). The values of k for tCho, MR volume and ADC were 0.31, 0.38, and 0.18 indicating fair, moderate, and slight agreement, respectively with pathological response. Moderate agreement (k = 0.44) was observed between clinical and pathological responses. Our study demonstrated that both tCho and ADC are strong predictors of assessment of early pathological and clinical responses. Multi-parametric approach yielded 100% specificity in predicting clinical response. Following III NACT, MR volume emerged as highly suitable predictor for both clinical and pathological assessments. PCA demonstrated separate clusters of pR vs. pNR and cR vs. cNR at post-therapy while with some overlap at pre-therapy.
Highlights
Neoadjuvant chemotherapy (NACT) is the standard care of treatment for patients with locally advanced breast cancer (LABC) owing to large tumor size, location and the risk of disease dissemination [1, 2]
The percentage of clinical responders were higher with estrogen receptor positive and progesterone receptor negative status, while patients with estrogen receptor negative and progesterone receptor negative statuses showed higher percentage of pathological response (Table 1)
Pre-menopausal women (71.4%) showed higher percentage of clinical response compared to post-menopausal women (52.4%), while a pathological response rate of 57.1% was achieved for patients with both menopausal statuses (Table 1)
Summary
Neoadjuvant chemotherapy (NACT) is the standard care of treatment for patients with locally advanced breast cancer (LABC) owing to large tumor size, location and the risk of disease dissemination [1, 2]. It is essential to monitor the tumor’s response sequentially after each NACT cycle to design patient tailored treatment. This would allow an early shift to alternative treatments and avoid toxicity of chemotherapy. Assessment of tumor response is carried out by physical examination and tumor size measurements by radiological techniques like X-ray mammography and ultrasound. These techniques do not accurately differentiate between chemotherapy-induced fibrosis and residual disease and both over- and under-estimation of tumor sizes have been documented [3,4,5]. Further late manifestation of changes in tumor size has been the limitation of these morphology based assessment methods [3,4,5]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have